{"url_path":"/sec/fbiop/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1429260/0001104659-26-061233-index.html","accession_number":"0001104659-26-061233","cik":"0001429260","ticker":"FBIO","issuer_name":"Fortress Biotech, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1429260/0001104659-26-061233-index.html","primary_entity_key":"0001429260","primary_entity_name":"Fortress Biotech, Inc."},"word_count":753,"has_tables":true,"body_markdown":"Item 6.      Exhibits\n\n**Exhibit Index**\n\n**Exhibit**\n**Number**\n\n  ​ ​ ​\n\n**Exhibit Title**\n\n \n\n \n\n \n\n[3.1](https://www.sec.gov/Archives/edgar/data/1429260/000119312511189437/dex31.htm)\n\n​\n\n[Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. (formerly Coronado Biosciences, Inc.) dated April 21, 2010 (incorporated by reference to Exhibit 3.1 of the Registrant’s Form 10 (file No. 000-54463) filed with the SEC on July 15, 2011).](https://www.sec.gov/Archives/edgar/data/1429260/000119312511189437/dex31.htm)\n\n​\n\n​\n\n​\n\n[3.2](https://www.sec.gov/Archives/edgar/data/1429260/000119312511189437/dex32.htm)\n\n​\n\n[First Certificate of Amendment of Amended and Restated Certificate of Incorporation, as amended, of Fortress Biotech, Inc. dated May 20, 2011 (incorporated by reference to Exhibit 3.2 of the Registrant’s Form 10 (file No. 000-54463) filed with SEC on July 15, 2011).](https://www.sec.gov/Archives/edgar/data/1429260/000119312511189437/dex32.htm)\n\n​\n\n​\n\n​\n\n[3.3](https://www.sec.gov/Archives/edgar/data/1429260/000114420414015803/v365741_ex3-8.htm)\n\n​\n\n[Second Certificate of Amendment of Amended and Restated Certificate of Incorporation, as amended, of Fortress Biotech, Inc. dated October 1, 2013 (incorporated by reference to Exhibit 3.8 of the Registrant’s Annual Report on Form 10-K (file No. 001-35366) filed with SEC on March 14, 2014).](https://www.sec.gov/Archives/edgar/data/1429260/000114420414015803/v365741_ex3-8.htm)\n\n​\n\n​\n\n​\n\n[3.4](https://www.sec.gov/Archives/edgar/data/1429260/000114420415025295/v408380_ex3-9.htm)\n\n​\n\n[Third Certificate of Amendment of Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. dated April 22, 2015 (incorporated by reference to Exhibit 3.9 of the Registrant’s Current Report on Form 8-K (file No. 001-35366) filed with SEC on April 27, 2015).](https://www.sec.gov/Archives/edgar/data/1429260/000114420415025295/v408380_ex3-9.htm)\n\n​\n\n​\n\n​\n\n[3.5](https://www.sec.gov/Archives/edgar/data/1429260/000110465920075304/tm2022881d1_ex3-1.htm)\n\n​\n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. dated June 18, 2020 (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (file No. 001-35366) filed with SEC on June 19, 2020).](https://www.sec.gov/Archives/edgar/data/1429260/000110465920075304/tm2022881d1_ex3-1.htm)\n\n​\n\n​\n\n​\n\n[3.6](https://www.sec.gov/Archives/edgar/data/1429260/000110465921084632/tm2120520d1_ex3-1.htm)\n\n​\n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. dated June 23, 2021 (incorporated by reference to Exhibit 3.1 of the Registrant’s Form 8-K (file No. 001-35366) filed with SEC on June 23, 2021).](https://www.sec.gov/Archives/edgar/data/1429260/000110465921084632/tm2120520d1_ex3-1.htm)\n\n​\n\n​\n\n​\n\n[3.7](https://www.sec.gov/Archives/edgar/data/1429260/000155837022010620/fbio-20220711xex3d1.htm)\n\n​\n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. dated July 8, 2022 (incorporated by reference to Exhibit 3.1 of the Registrant’s Form 8-K (file No. 001-35366) filed with SEC on July 11, 2022).](https://www.sec.gov/Archives/edgar/data/1429260/000155837022010620/fbio-20220711xex3d1.htm)\n\n​\n\n​\n\n​\n\n[3.8](https://www.sec.gov/Archives/edgar/data/1429260/000155837023016326/fbio-20231009xex3d1.htm)\n\n​\n\n[Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc. dated October 9, 2023 (incorporated by reference to Exhibit 3.1 of the Registrant’s Form 8-K (file No. 001-35366) filed with SEC on October 10, 2023.](https://www.sec.gov/Archives/edgar/data/1429260/000155837023016326/fbio-20231009xex3d1.htm)\n\n​\n\n​\n\n​\n\n[3.9](https://www.sec.gov/Archives/edgar/data/1429260/000155837024009466/fbio-20240619xex3d2.htm)\n\n​\n\n[Fourth Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 of the Registrant’s Current Report on Form 8-K (file No. 001-35366) filed with SEC on June 25, 2024).](https://www.sec.gov/Archives/edgar/data/1429260/000155837024009466/fbio-20240619xex3d2.htm)\n\n​\n\n​\n\n​\n\n88\n\n[Table of Contents](#TOC)\n\n[10.1](fbio-20260331xex10d1.htm)\n\n​\n\n[Asset Purchase Agreement, dated February 22, 2026, between Cyprium Therapeutics, Inc. and buyer.(*)(***)](fbio-20260331xex10d1.htm)\n\n​\n\n​\n\n​\n\n[10.2](fbio-20260331xex10d2.htm)\n\n​\n\n[Second Amendment to Credit Agreement, dated as of February 22, 2026, by and among Fortress Biotech, Inc., the lenders from time to time thereto, and Oaktree Fund Administration, LLC.(*)](fbio-20260331xex10d2.htm)\n\n​\n\n​\n\n​\n\n[31.1](fbio-20260331xex31d1.htm)\n\n \n\n[Certification of Chairman, President and Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.(*)](fbio-20260331xex31d1.htm)\n\n​\n\n​\n\n​\n\n[31.2](fbio-20260331xex31d2.htm)\n\n​\n\n[Certification of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.(*)](fbio-20260331xex31d2.htm)\n\n​\n\n​\n\n​\n\n[32.1](fbio-20260331xex32d1.htm)\n\n \n\n[Certification of the Chairman, President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.(**)](fbio-20260331xex32d1.htm)\n\n \n\n \n\n \n\n[32.2](fbio-20260331xex32d2.htm)\n\n \n\n[Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.(**)](fbio-20260331xex32d2.htm)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n101.INS\n\n \n\nInline XBRL Instance Document.(*)\n\n \n\n \n\n \n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema Document.(*)\n\n \n\n \n\n \n\n101.CAL\n\n \n\nInline XBRL Taxonomy Extension Calculation Linkbase Document.(*)\n\n \n\n \n\n \n\n101.DEF\n\n \n\nInline XBRL Taxonomy Extension Definition Linkbase Document.(*)\n\n \n\n \n\n \n\n101.LAB\n\n \n\nInline XBRL Taxonomy Extension Label Linkbase Document.(*)\n\n \n\n \n\n \n\n101.PRE\n\n \n\nInline XBRL Taxonomy Extension Presentation Linkbase Document.(*)\n\n​\n\n​\n\n​\n\n104\n\n​\n\nCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).\n\n​\n\n* Filed herewith.\n\n**Furnished herewith.\n\n*** Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K.\n\n​\n\n​\n\n89\n\n[Table of Contents](#TOC)\n\n​\n\n​\n\n​\n\n​\n\n**SIGNATURES**\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n​\n\nMay 14, 2026\n\nFORTRESS BIOTECH, INC.\n\n \n\n \n\n \n\n \n\nBy: \n\n/s/ Lindsay A. Rosenwald, M.D.\n\n \n\n \n\nLindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer (Principal Executive Officer)\n\n \n\n \n\n \n\nMay 14, 2026\n\nBy:\n\n/s/ David Jin\n\n \n\n \n\nDavid Jin, Chief Financial Officer (Principal Financial Officer)\n\n​\n\n​\n\n​\n\n​\n\n90"}